查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1530922

胃輕癱治療市場 - 全球產業分析、規模、佔有率、成長、趨勢和預測，2024-2034 年

Gastroparesis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 153 Pages | 商品交期: 2-10個工作天內

價格

胃輕癱治療市場 - 報告範圍

TMR 關於全球胃輕癱治療市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2024 年至 2034 年預測期內市場指標的寶貴見解。 -2034年期間，考慮2024年為基準年，2034年為預測年。該報告也提供了2024年至2034年全球胃輕癱治療市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。次要研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解胃輕癱治療市場。

市場概況
2023年市場價值 63 億美元
2034 年市場價值 103 億美元
複合年成長率 4.6%

該報告深入探討了全球胃輕癱治療市場的競爭格局。全球胃輕癱治療市場的主要參與者已經確定，並且每位參與者都根據各種屬性進行了分析。公司概況、財務狀況、近期發展和 SWOT 是本報告中介紹的全球胃輕癱治療市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2020-2034年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：依藥物類別

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依藥品類別，2020-2034
    • 促動力劑
    • 止吐藥
    • 質子幫浦抑制劑
    • 其他（肉毒桿菌注射等）
  • 市場吸引力：按藥品類別

第 7 章：全球市場分析與預測：按疾病適應症

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依疾病適應症，2020-2034
    • 糖尿病胃輕癱
    • 特發性胃輕癱
    • 術後胃輕癱
  • 市場吸引力：依疾病適應症分類

第 8 章：全球市場分析與預測：按類型

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按類型，2020-2034
    • 非處方藥
    • 處方藥
  • 市場吸引力：按類型

第 9 章：全球市場分析與預測：按給藥途徑

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依給藥途徑，2020-2034年
    • 口服
    • 注射劑
    • 鼻腔
  • 市場吸引力：依給藥途徑分類

第 10 章：全球市場分析與預測：按配銷通路

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按配銷通路，2020-2034
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 市場吸引力：按配銷通路分類

第 11 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2020-2034
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按地區

第 12 章：北美市場分析與預測

第 13 章：歐洲市場分析與預測

第 14 章：亞太市場分析與預測

第 15 章：拉丁美洲市場分析與預測

第 16 章：中東和非洲市場分析與預測

第17章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2023）
  • 公司簡介
    • Abbott Laboratories
    • AbbVie Inc.
    • AstraZeneca plc
    • Bayer AG
    • Cipla Limited
    • Evoke Pharma
    • Pfizer Inc.
    • Salix Pharmaceuticals, Inc.
    • The Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: TMRGL39305

Gastroparesis Treatment Market - Scope of Report

TMR's report on the global gastroparesis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global gastroparesis treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global gastroparesis treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the gastroparesis treatment market.

Market Snapshot
Market Value in 2023US$ 6.3 Bn
Market Value in 2034US$ 10.3 Bn
CAGR4.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global gastroparesis treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global gastroparesis treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global gastroparesis treatment market.

The report delves into the competitive landscape of the global gastroparesis treatment market. Key players operating in the global gastroparesis treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global gastroparesis treatment market profiled in this report.

Key Questions Answered in Global gastroparesis treatment Market Report:

  • What is the sales/revenue generated by gastroparesis treatment across all regions during the forecast period?
  • What are the opportunities in the global gastroparesis treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Gastroparesis Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global gastroparesis treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global gastroparesis treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global gastroparesis treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Gastroparesis Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Gastroparesis Treatment Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Gastroparesis Treatment Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2020-2034
    • 6.3.1. Prokinetic Agents
    • 6.3.2. Antiemetic Drugs
    • 6.3.3. Proton Pump Inhibitors
    • 6.3.4. Others (Botulinum Toxin Injections, etc.)
  • 6.4. Market Attractiveness, by Drug Class

7. Global Gastroparesis Treatment Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2020-2034
    • 7.3.1. Diabetes Gastroparesis
    • 7.3.2. Idiopathic Gastroparesis
    • 7.3.3. Post-surgical Gastroparesis
  • 7.4. Market Attractiveness, by Disease Indication

8. Global Gastroparesis Treatment Market Analysis and Forecast, By Type

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, By Type, 2020-2034
    • 8.3.1. Over-the-Counter Drugs
    • 8.3.2. Prescription Drugs
  • 8.4. Market Attractiveness, By Type

9. Global Gastroparesis Treatment Market Analysis and Forecast, by Route of Administration

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 9.3.1. Oral
    • 9.3.2. Injectables
    • 9.3.3. Nasal
  • 9.4. Market Attractiveness, by Route of Administration

10. Global Gastroparesis Treatment Market Analysis and Forecast, by Distribution Channel

  • 10.1. Introduction and Definitions
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Attractiveness, by Distribution Channel

11. Global Gastroparesis Treatment Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region, 2020-2034
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness, by Region

12. North America Gastroparesis Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2020-2034
    • 12.2.1. Prokinetic Agents
    • 12.2.2. Antiemetic Drugs
    • 12.2.3. Proton Pump Inhibitors
    • 12.2.4. Others (Botulinum Toxin Injections, etc.)
  • 12.3. Market Attractiveness, by Drug Class
  • 12.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 12.4.1. Diabetes Gastroparesis
    • 12.4.2. Idiopathic Gastroparesis
    • 12.4.3. Post-surgical Gastroparesis
  • 12.5. Market Attractiveness, by Disease Indication
  • 12.6. Market Value Forecast, By Type, 2020-2034
    • 12.6.1. Over-the-Counter Drugs
    • 12.6.2. Prescription Drugs
  • 12.7. Market Attractiveness, By Type
  • 12.8. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.8.1. Oral
    • 12.8.2. Injectables
    • 12.8.3. Nasal
  • 12.9. Market Attractiveness, by Route of Administration
  • 12.10. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.10.1. Hospital Pharmacies
    • 12.10.2. Retail Pharmacies
    • 12.10.3. Online Pharmacies
  • 12.11. Market Attractiveness, by Distribution Channel
  • 12.12. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.12.1. U.S.
    • 12.12.2. Canada
  • 12.13. Market Attractiveness Analysis
    • 12.13.1. By Drug Class
    • 12.13.2. By Disease Indication
    • 12.13.3. By Type
    • 12.13.4. By Route of Administration
    • 12.13.5. By Distribution Channel
    • 12.13.6. By Country

13. Europe Gastroparesis Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2020-2034
    • 13.2.1. Prokinetic Agents
    • 13.2.2. Antiemetic Drugs
    • 13.2.3. Proton Pump Inhibitors
    • 13.2.4. Others (Botulinum Toxin Injections, etc.)
  • 13.3. Market Attractiveness, by Drug Class
  • 13.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 13.4.1. Diabetes Gastroparesis
    • 13.4.2. Idiopathic Gastroparesis
    • 13.4.3. Post-surgical Gastroparesis
  • 13.5. Market Attractiveness, by Disease Indication
  • 13.6. Market Value Forecast, By Type, 2020-2034
    • 13.6.1. Over-the-Counter Drugs
    • 13.6.2. Prescription Drugs
  • 13.7. Market Attractiveness, By Type
  • 13.8. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.8.1. Oral
    • 13.8.2. Injectables
    • 13.8.3. Nasal
  • 13.9. Market Attractiveness, by Route of Administration
  • 13.10. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.10.1. Hospital Pharmacies
    • 13.10.2. Retail Pharmacies
    • 13.10.3. Online Pharmacies
  • 13.11. Market Attractiveness, by Distribution Channel
  • 13.12. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.12.1. Germany
    • 13.12.2. U.K.
    • 13.12.3. France
    • 13.12.4. Italy
    • 13.12.5. Spain
    • 13.12.6. Rest of Europe
  • 13.13. Market Attractiveness Analysis
    • 13.13.1. By Drug Class
    • 13.13.2. By Disease Indication
    • 13.13.3. By Type
    • 13.13.4. By Route of Administration
    • 13.13.5. By Distribution Channel
    • 13.13.6. By Country/Sub-region

14. Asia Pacific Gastroparesis Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2020-2034
    • 14.2.1. Prokinetic Agents
    • 14.2.2. Antiemetic Drugs
    • 14.2.3. Proton Pump Inhibitors
    • 14.2.4. Others (Botulinum Toxin Injections, etc.)
  • 14.3. Market Attractiveness, by Drug Class
  • 14.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 14.4.1. Diabetes Gastroparesis
    • 14.4.2. Idiopathic Gastroparesis
    • 14.4.3. Post-surgical Gastroparesis
  • 14.5. Market Attractiveness, by Disease Indication
  • 14.6. Market Value Forecast, By Type, 2020-2034
    • 14.6.1. Over-the-Counter Drugs
    • 14.6.2. Prescription Drugs
  • 14.7. Market Attractiveness, By Type
  • 14.8. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.8.1. Oral
    • 14.8.2. Injectables
    • 14.8.3. Nasal
  • 14.9. Market Attractiveness, by Route of Administration
  • 14.10. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.10.1. Hospital Pharmacies
    • 14.10.2. Retail Pharmacies
    • 14.10.3. Online Pharmacies
  • 14.11. Market Attractiveness, by Distribution Channel
  • 14.12. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.12.1. China
    • 14.12.2. Japan
    • 14.12.3. India
    • 14.12.4. Australia & New Zealand
    • 14.12.5. Rest of Asia Pacific
  • 14.13. Market Attractiveness Analysis
    • 14.13.1. By Drug Class
    • 14.13.2. By Disease Indication
    • 14.13.3. By Type
    • 14.13.4. By Route of Administration
    • 14.13.5. By Distribution Channel
    • 14.13.6. By Country/Sub-region

15. Latin America Gastroparesis Treatment Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Class, 2020-2034
    • 15.2.1. Prokinetic Agents
    • 15.2.2. Antiemetic Drugs
    • 15.2.3. Proton Pump Inhibitors
    • 15.2.4. Others (Botulinum Toxin Injections, etc.)
  • 15.3. Market Attractiveness, by Drug Class
  • 15.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 15.4.1. Diabetes Gastroparesis
    • 15.4.2. Idiopathic Gastroparesis
    • 15.4.3. Post-surgical Gastroparesis
  • 15.5. Market Attractiveness, by Disease Indication
  • 15.6. Market Value Forecast, By Type, 2020-2034
    • 15.6.1. Over-the-Counter Drugs
    • 15.6.2. Prescription Drugs
  • 15.7. Market Attractiveness, By Type
  • 15.8. Market Value Forecast, by Route of Administration, 2020-2034
    • 15.8.1. Oral
    • 15.8.2. Injectables
    • 15.8.3. Nasal
  • 15.9. Market Attractiveness, by Route of Administration
  • 15.10. Market Value Forecast, by Distribution Channel, 2020-2034
    • 15.10.1. Hospital Pharmacies
    • 15.10.2. Retail Pharmacies
    • 15.10.3. Online Pharmacies
  • 15.11. Market Attractiveness, by Distribution Channel
  • 15.12. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.12.1. Brazil
    • 15.12.2. Mexico
    • 15.12.3. Rest of Latin America
  • 15.13. Market Attractiveness Analysis
    • 15.13.1. By Drug Class
    • 15.13.2. By Disease Indication
    • 15.13.3. By Type
    • 15.13.4. By Route of Administration
    • 15.13.5. By Distribution Channel
    • 15.13.6. By Country/Sub-region

16. Middle East & Africa Gastroparesis Treatment Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Drug Class, 2020-2034
    • 16.2.1. Prokinetic Agents
    • 16.2.2. Antiemetic Drugs
    • 16.2.3. Proton Pump Inhibitors
    • 16.2.4. Others (Botulinum Toxin Injections, etc.)
  • 16.3. Market Attractiveness, by Drug Class
  • 16.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 16.4.1. Diabetes Gastroparesis
    • 16.4.2. Idiopathic Gastroparesis
    • 16.4.3. Post-surgical Gastroparesis
  • 16.5. Market Attractiveness, by Disease Indication
  • 16.6. Market Value Forecast, By Type, 2020-2034
    • 16.6.1. Over-the-Counter Drugs
    • 16.6.2. Prescription Drugs
  • 16.7. Market Attractiveness, By Type
  • 16.8. Market Value Forecast, by Route of Administration, 2020-2034
    • 16.8.1. Oral
    • 16.8.2. Injectables
    • 16.8.3. Nasal
  • 16.9. Market Attractiveness, by Route of Administration
  • 16.10. Market Value Forecast, by Distribution Channel, 2020-2034
    • 16.10.1. Hospital Pharmacies
    • 16.10.2. Retail Pharmacies
    • 16.10.3. Online Pharmacies
  • 16.11. Market Attractiveness, by Distribution Channel
  • 16.12. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 16.12.1. GCC Countries
    • 16.12.2. South Africa
    • 16.12.3. Rest of Middle East & Africa
  • 16.13. Market Attractiveness Analysis
    • 16.13.1. By Drug Class
    • 16.13.2. By Disease Indication
    • 16.13.3. By Type
    • 16.13.4. By Route of Administration
    • 16.13.5. By Distribution Channel
    • 16.13.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 17.2. Market Share Analysis, by Company (2023)
  • 17.3. Company Profiles
    • 17.3.1. Abbott Laboratories
      • 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.1.2. Product Portfolio
      • 17.3.1.3. Financial Overview
      • 17.3.1.4. SWOT Analysis
      • 17.3.1.5. Strategic Overview
    • 17.3.2. AbbVie Inc.
      • 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.2.2. Product Portfolio
      • 17.3.2.3. Financial Overview
      • 17.3.2.4. SWOT Analysis
      • 17.3.2.5. Strategic Overview
    • 17.3.3. AstraZeneca plc
      • 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.3.2. Product Portfolio
      • 17.3.3.3. Financial Overview
      • 17.3.3.4. SWOT Analysis
      • 17.3.3.5. Strategic Overview
    • 17.3.4. Bayer AG
      • 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.4.2. Product Portfolio
      • 17.3.4.3. Financial Overview
      • 17.3.4.4. SWOT Analysis
      • 17.3.4.5. Strategic Overview
    • 17.3.5. Cipla Limited
      • 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.5.2. Product Portfolio
      • 17.3.5.3. Financial Overview
      • 17.3.5.4. SWOT Analysis
      • 17.3.5.5. Strategic Overview
    • 17.3.6. Evoke Pharma
      • 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.6.2. Product Portfolio
      • 17.3.6.3. Financial Overview
      • 17.3.6.4. SWOT Analysis
      • 17.3.6.5. Strategic Overview
    • 17.3.7. Pfizer Inc.
      • 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.7.2. Product Portfolio
      • 17.3.7.3. Financial Overview
      • 17.3.7.4. SWOT Analysis
      • 17.3.7.5. Strategic Overview
    • 17.3.8. Salix Pharmaceuticals, Inc.
      • 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.8.2. Product Portfolio
      • 17.3.8.3. Financial Overview
      • 17.3.8.4. SWOT Analysis
      • 17.3.8.5. Strategic Overview
    • 17.3.9. The Takeda Pharmaceutical Company Limited
      • 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.9.2. Product Portfolio
      • 17.3.9.3. Financial Overview
      • 17.3.9.4. SWOT Analysis
      • 17.3.9.5. Strategic Overview
    • 17.3.10. Teva Pharmaceutical Industries Ltd.
      • 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.10.2. Product Portfolio
      • 17.3.10.3. Financial Overview
      • 17.3.10.4. SWOT Analysis
      • 17.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 02: Global Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
  • Table 03: Global Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 04: Global Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Type, 2020-2034
  • Table 05: Global Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 06: Global Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 07: North America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 08: North America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 09: North America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
  • Table 10: North America Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Type, 2020-2034
  • Table 11: North America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 12: North America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Europe Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Europe Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 15: Europe Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
  • Table 16: Europe Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Type, 2020-2034
  • Table 17: Europe Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 18: Europe Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 19: Asia Pacific Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 20: Asia Pacific Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 21: Asia Pacific Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
  • Table 22: Asia Pacific Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Type, 2020-2034
  • Table 23: Asia Pacific Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 24: Asia Pacific Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 25: Latin America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 26: Latin America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 27: Latin America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
  • Table 28: Latin America Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Type, 2020-2034
  • Table 29: Latin America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 30: Latin America Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 31: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 32: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 33: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
  • Table 34: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast, By Type, 2020-2034
  • Table 35: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 36: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Gastroparesis Treatment Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Gastroparesis Treatment Market Revenue (US$ Bn), by Drug Class, 2023
  • Figure 03: Global Gastroparesis Treatment Market Value Share, by Drug Class, 2023
  • Figure 04: Global Gastroparesis Treatment Market Revenue (US$ Bn), by Disease Indication, 2023
  • Figure 05: Global Gastroparesis Treatment Market Value Share, by Disease Indication, 2023
  • Figure 06: Global Gastroparesis Treatment Market Revenue (US$ Bn), By Type, 2023
  • Figure 07: Global Gastroparesis Treatment Market Value Share, By Type, 2023
  • Figure 08: Global Gastroparesis Treatment Market Revenue (US$ Bn), by Route of Administration, 2023
  • Figure 09: Global Gastroparesis Treatment Market Value Share, by Route of Administration, 2023
  • Figure 10: Global Gastroparesis Treatment Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 11: Global Gastroparesis Treatment Market Value Share, by Distribution Channel, 2023
  • Figure 12: Global Gastroparesis Treatment Market Value Share, by Region, 2023
  • Figure 13: Global Gastroparesis Treatment Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 14: Global Gastroparesis Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 15: Global Gastroparesis Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 16: Global Gastroparesis Treatment Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 17: Global Gastroparesis Treatment Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 18: Global Gastroparesis Treatment Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 19: Global Gastroparesis Treatment Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 20: Global Gastroparesis Treatment Market Revenue (US$ Bn), by Route of Administration, 2023
  • Figure 21: Global Gastroparesis Treatment Market Value Share, by Route of Administration, 2023
  • Figure 22: Global Gastroparesis Treatment Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 23: Global Gastroparesis Treatment Market Value Share, by Distribution Channel, 2023
  • Figure 24: Global Gastroparesis Treatment Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 25: Global Gastroparesis Treatment Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 26: North America Gastroparesis Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 27: North America Gastroparesis Treatment Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 28: North America Gastroparesis Treatment Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 29: North America Gastroparesis Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 30: North America Gastroparesis Treatment Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 31: North America Gastroparesis Treatment Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 32: North America Gastroparesis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 33: North America Gastroparesis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 34: North America Gastroparesis Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 35: North America Gastroparesis Treatment Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 36: North America Gastroparesis Treatment Market Attractiveness Analysis, By Type, 2023-2034
  • Figure 37: North America Gastroparesis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 38: North America Gastroparesis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 39: Europe Gastroparesis Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 40: Europe Gastroparesis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 41: Europe Gastroparesis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 42: Europe Gastroparesis Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 43: Europe Gastroparesis Treatment Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 44: Europe Gastroparesis Treatment Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 45: Europe Gastroparesis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 46: Europe Gastroparesis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 47: Europe Gastroparesis Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 48: Europe Gastroparesis Treatment Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 49: Europe Gastroparesis Treatment Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 50: Europe Gastroparesis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 51: Europe Gastroparesis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 52: Asia Pacific Gastroparesis Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 53: Asia Pacific Gastroparesis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 54: Asia Pacific Gastroparesis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 55: Asia Pacific Gastroparesis Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 56: Asia Pacific Gastroparesis Treatment Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 57: Asia Pacific Gastroparesis Treatment Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 58: Asia Pacific Gastroparesis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 59: Asia Pacific Gastroparesis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 60: Asia Pacific Gastroparesis Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 61: Asia Pacific Gastroparesis Treatment Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 62: Asia Pacific Gastroparesis Treatment Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 63: Asia Pacific Gastroparesis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 64: Asia Pacific Gastroparesis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 65: Latin America Gastroparesis Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 66: Latin America Gastroparesis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 67: Latin America Gastroparesis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 68: Latin America Gastroparesis Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 69: Latin America Gastroparesis Treatment Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 70: Latin America Gastroparesis Treatment Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 71: Latin America Gastroparesis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 72: Latin America Gastroparesis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 73: Latin America Gastroparesis Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 74: Latin America Gastroparesis Treatment Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 75: Latin America Gastroparesis Treatment Market Attractiveness Analysis, By Type, 2023-2034
  • Figure 76: Latin America Gastroparesis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 77: Latin America Gastroparesis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 78: Middle East & Africa Gastroparesis Treatment Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 79: Middle East & Africa Gastroparesis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 80: Middle East & Africa Gastroparesis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 81: Middle East & Africa Gastroparesis Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 82: Middle East & Africa Gastroparesis Treatment Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 83: Middle East & Africa Gastroparesis Treatment Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 84: Middle East & Africa Gastroparesis Treatment Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 85: Middle East & Africa Gastroparesis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 86: Middle East & Africa Gastroparesis Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 87: Middle East & Africa Gastroparesis Treatment Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 88: Middle East & Africa Gastroparesis Treatment Market Attractiveness Analysis, By Type, 2023-2034
  • Figure 89: Middle East & Africa Gastroparesis Treatment Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 90: Middle East & Africa Gastroparesis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034